Moleculin Biotech (MBRX) to Release Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is scheduled to issue its quarterly earnings data after the market closes on Friday, November 8th. Analysts expect the company to announce earnings of ($2.44) per share for the quarter.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, analysts expect Moleculin Biotech to post $-9 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Moleculin Biotech Price Performance

MBRX stock traded down $0.01 on Wednesday, reaching $2.44. The company had a trading volume of 405 shares, compared to its average volume of 30,048. The company’s fifty day moving average is $2.50 and its 200 day moving average is $3.40. Moleculin Biotech has a 1 year low of $2.12 and a 1 year high of $15.75.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Moleculin Biotech in a research note on Tuesday. They issued a “sell” rating for the company.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.